Drug Profile
Nicotine transmucosal - Bionex Pharmaceuticals
Latest Information Update: 08 Jan 2022
Price :
$50
*
At a glance
- Originator Bionex Pharmaceuticals
- Developer Bionex Pharmaceuticals; Rutgers
- Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Smoking withdrawal
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for clinical-Phase-Unknown development in Smoking-withdrawal in USA (Transmucosal, Film)
- 12 Dec 2016 Chemical structure information added
- 18 Nov 2016 Clinical trials in Smoking withdrawal in USA (Transmucosal) before November 2016